Galmed Pharmaceuticals Ltd. (NASDAQ:EOCN – Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 7,516 shares, a drop of 46.7% from the September 30th total of 14,112 shares. Based on an average trading volume of 9,029 shares, the short-interest ratio is currently 0.8 days. Approximately 0.9% of the company’s stock are sold short.
Galmed Pharmaceuticals Trading Down 3.7%
NASDAQ EOCN traded down $0.12 during midday trading on Friday, hitting $3.10. The company had a trading volume of 3,112 shares, compared to its average volume of 7,782. The firm has a 50-day moving average price of $4.05 and a 200-day moving average price of $4.71. Galmed Pharmaceuticals has a twelve month low of $2.33 and a twelve month high of $12.32. The company has a market capitalization of $3.22 million, a PE ratio of -0.20 and a beta of 0.66.
Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) last released its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, beating the consensus estimate of ($3.12) by $0.26.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has an average rating of “Sell”.
Check Out Our Latest Research Report on Galmed Pharmaceuticals
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
